Kedrion Biopharma
Professor Tim Sandle, Ph.D., CBiol, FIScT, serves as an Associate Professor at UCL's School of Pharmacy specializing in Pharmaceutical Microbiology and Sterility Assurance. With extensive experience in quality assurance and compliance, Tim Sandle currently holds the position of Head of QA GxP Compliance, Sterility Assurance, and Quality Risk Management at Kedrion Biopharma. Tim Sandle also founded Pharmaceutical Microbiology Resources, is the Editor of GMP Review, and has contributed as a journalist for Digital Journal. Tim Sandle's prior roles include key leadership positions at Bio Products Laboratory Limited, where responsibilities encompassed continuous improvement and microbiological validation. Academic credentials include a Ph.D. in Bioscience from Keele University and extensive teaching experience in pharmaceutical microbiology.
This person is not in any teams
This person is not in any offices
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.